Metabolic dysfunction-associated fatty liver disease was significantly associated with an increased risk of subclinical carotid atherosclerosis (OR 1.66).
Cross-Sectional (n=153,482)
Yes
Does metabolic dysfunction-associated fatty liver disease (MAFLD) increase the risk of subclinical carotid atherosclerosis in adults?
Metabolic dysfunction-associated fatty liver disease (MAFLD) is independently associated with an increased risk of prevalent and incident subclinical carotid atherosclerosis, particularly in younger adults and those with severe hepatic steatosis.
Odds Ratio: 1.66 (95% CI 1.62–1.7)
Absolute Event Rate: 50.52% vs 37.24%
p-value: p=<0.001
Background and aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to substitute NAFLD in 2020. This new term highlights the systematic metabolic disturbances that accompany fatty liver. We evaluated the correlations between MAFLD and subclinical carotid atherosclerosis (SCA) based on a nationwide health examination population in China. Methods: We performed a nationwide cross-sectional population and a Beijing retrospective cohort from 2009 to 2017. SCA was defined as elevated carotid intima-media thickness. The multivariable logistic and Cox models were used to analyze the association between MAFLD and SCA. Results: 153,482 participants were included in the cross-sectional study. MAFLD was significantly associated with SCA in fully adjusted models, with an odds ratio of 1.66; 95% confidence interval (CI): 1.62-1.70. This association was consistent in the cohort, with a hazard ratio (HR) of 1.31. The association between baseline MAFLD and incident SCA increased with hepatic steatosis severity. Subgroup analysis showed an interaction between age and MAFLD, with a higher risk in younger groups (HR:1.67, 95% CI: 1.17-2.40). Conclusion: In this large cross-section and cohort study, MAFLD was significantly associated with the presence and development of SCA. Further, the risk was higher among MAFLD individuals with high hepatic steatosis index and young adults.
Lei et al. (Tue,) conducted a cross-sectional in Metabolic dysfunction-associated fatty liver disease (MAFLD) (n=153,482). Metabolic dysfunction-associated fatty liver disease (MAFLD) vs. Non-MAFLD was evaluated on Subclinical carotid atherosclerosis (SCA) (OR 1.66, 95% CI 1.62-1.70, p=<0.001). Metabolic dysfunction-associated fatty liver disease was significantly associated with an increased risk of subclinical carotid atherosclerosis (OR 1.66).